ARS Pharmaceuticals, Inc. (SPRY) Revenue 2021–2025
ARS Pharmaceuticals, Inc. (SPRY) annual revenue history from SEC filings — each fiscal year as reported, with year-over-year change.
$84.3MFY2025 · since FY2021: $5.5M → $84.3M
| Fiscal year | Value | YoY |
|---|---|---|
| FY2025 | $84.3M | -5.5% |
| FY2024 | $89.1M | +297063.3% |
| FY2023 | $30,000 | -97.7% |
| FY2022 | $1.3M | -76.1% |
| FY2021 | $5.5M | — |
Source: SEC XBRL filings · For reference only · Not investment advice
More SPRY financial trends
SPRY Net incomeSPRY Net marginSPRY Gross profitSPRY Gross marginSPRY Operating incomeSPRY Operating marginSPRY Operating cash flowSPRY Free cash flowSPRY Capital expendituresSPRY Return on equitySPRY Stock buybacksSPRY Dividends paidSPRY Total assetsSPRY Total liabilitiesSPRY Shareholders’ equitySPRY overview →